Prognostic role of EAONO/JOS, STAMCO, and ChOLE Staging for Exclusive Endoscopic and Endoscopic‐Microscopic Tympanoplasty. (22nd January 2023)

• Record Type: Journal Article
• Authors: Fermi, Matteo; Bassano, Edoardo; Villari, Domenico; Capriotti, Vincenzo; Calvaruso, Federico; Bonali, Marco; Alicandri‐Ciufelli, Matteo; Marchioni, Daniele; Presutti, Livio
• Is Part Of: Otolaryngology--head and neck surgery. Volume 168:Number 4(2023)
• Page Start: 829
• Page End: 838
• Publication Date: 2023-01-22
• Subjects: cholesteatoma -- cholesteatoma staging -- endoscopic ear surgery -- recurrence -- residual cholesteatoma; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1002/ohn.171
• Languages: English
• ISSNs: 0194-5998

Abstract

Abstract: Objective: The aim of the study is to evaluate cholesteatoma's surgical outcomes in patients treated with endoscopic ear surgery (EES) or a combined endoscopic‐microscopic approach (cEMA) according to STAM, STAMCO, ChOLE, and EAONO/JOS system (EJS) classifications and staging. Study Design: Retrospective study. Setting: Monocentric study in a tertiary referral center. Methods: One‐hundred sixty‐eight patients who underwent EES or cEMA for cholesteatoma between 2010 and 2018 were classified according to the abovementioned classification and staging. Data on cholesteatoma's recurrence and residual rates were collected. Inferential statistical analysis was performed to evaluate surgical outcomes and the prognostic value of classifications and staging. Results: The recurrence rate was significantly lower in cholesteatomas classified in EJS stage 1 (2.6%) and STAM stage 1 (0%). A comparison of the different stages of the disease showed a significantly lower recurrence only for stage 1 versus the superior stages of both classifications. Involvement of mastoid bone was associated with a higher risk of recurrence (odds ratio [OR]: 4.12; p = .031). Attical involvement was associated with a higher risk of residual cholesteatoma (OR: 1.165; p = .046). Conclusion: EES or cEMA represents an effective treatment for middle ear cholesteatoma. The STAM classification and the EJS have shown a prognostic value, with STAM 1 and EAONO‐JOS 1 stages associated with a better prognosis. Mastoid involvement represents a risk factor for recurrence. Attic localization is associated with residual disease. Localization at difficult access sites did not implicate a higher risk for recurrence or residual. ChOLE classification, Ossicular chain status, and complication status did not provide prognostic information regarding recurrence or residual cholesteatoma.